In a classic case of one hand not knowing what the other is doing, a Virginia doctor (in this case, our esteemed Dr. Paul Marik) has been awarded a legislative commendation for his study into alternative treatments of COVID-19 just a few days before the state’s medical licensing board informed him he was under investigation for misconduct— for the same work.

By mentioning a Pfizer drug by name in his State of the Union Address, Biden showed the clear bias this government has for expensive, high-profit drugs while ignoring lower-cost treatments.

A renowned, highly accomplished Maine physician's mental health is being questioned because she went 'off-script' to save her patients' lives.

Regular use of ivermectin as a prophylactic was associated with significantly reduced COVID-19 infection, hospitalization and mortality rates. The results are in from the world’s largest study of ivermectin for COVID-19.

Nebraska’s Attorney General issued an opinion on the “Prescription of Ivermectin and Hydroxychloroquine as Off-Label Medicines for the Prevention or Treatment of Covid-19.

Authors: Ader F, Hites M, Poissy J, Belhadi D, Diallo A, Staub T PMID: 34534511 PMCID: PMC8439621 DOI: 10.1016/S1473-3099(21)00485-0 Abstract Background: The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital [...]

To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences.

Authors: Niaee MS, Gheibl N, Namdar P, Allami A, Javadi A. DOI: 10.4103/1995-7645.318304 Abstract Permissions ORIGINAL ARTICLE Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients A randomized multi-center clinical trial Niaee, Morteza Shakhsi1; Namdar, Peyman2; Allami, Abbas3; Zolghadr, Leila4; Javadi, Amir5; Karampour, Amin3; Varnaseri, Mehran6; Bijani, Behzad7; Cheraghi, Fatemeh1; Naderi, Yazdan8; Amini, Fatemeh9; [...]

Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.

Authors: Shoaibi A, Fortin S, Weinstein R, Berlin JA PMID: 33982938 DOI: 10.14309/ajg.0000000000001153 Abstract Introduction: Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, [...]